Laurus Labs Limited
LAURUSLABS · Pharma · NSE
₹1,131
Current Market Price
Fair Value (DCF)
₹415
Margin of Safety
-63.3%
Updated just now
YieldIQ Score
40/100
Piotroski F-Score
5/9
Economic Moat
Narrow
Confidence
26%
ROE
7.8%
Debt/Equity
0.00
WACC
9.8%
Market Cap
₹0.61 Lakh Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
11.9%
Return on capital employed
EV / EBITDA
39.0×
Enterprise multiple
Debt / EBITDA
1.7×
Leverage vs earnings
Interest Coverage
3.3×
EBIT covers interest
Current Ratio
1.22×
Short-term liquidity
Asset Turnover
0.69×
Revenue per ₹ of assets
Revenue CAGR (3Y)
—
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹1,131.25
Bear case
₹240.54
MoS -370.3%
Base case
₹415.37
MoS -172.3%
Bull case
₹579.98
MoS -95.0%
Ratio Trends
LAURUSLABS · last 8 annual periods
ROE
7.8%
ROCE
15.2%
Operating Margin
—
Debt / Equity
0.60×
PE
1.9×
EV / EBITDA
0.8×
Historical Financials
LAURUSLABS · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹4769 Cr | ₹4936 Cr | ₹1279 Cr | ₹1415 Cr | ₹5508 Cr | +3.7% |
| EBITDA | — | ₹1411 Cr | ₹1556 Cr | ₹793 Cr | ₹1121 Cr | -5.6% |
| EBIT | ₹1341 Cr | ₹1186 Cr | ₹178 Cr | ₹206 Cr | — | -37.4% |
| PAT | ₹956 Cr | ₹832 Cr | ₹102 Cr | ₹121 Cr | ₹358 Cr | -21.8% |
| EPS (diluted) | ₹17.77 | ₹15.35 | ₹1.88 | ₹2.25 | — | -40.3% |
| CFO | ₹694 Cr | ₹911 Cr | ₹882 Cr | ₹659 Cr | ₹602 Cr | -3.5% |
| CapEx | — | — | — | — | ₹-641 Cr | — |
| FCF | — | — | — | — | ₹-39.4 Cr | — |
| Total Assets | — | ₹6968 Cr | ₹6958 Cr | ₹7667 Cr | ₹9336 Cr | +7.6% |
| Total Debt | — | — | ₹1116 Cr | ₹1559 Cr | ₹2764 Cr | +25.4% |
| Shareholders' Equity | — | — | ₹4057 Cr | ₹4207 Cr | ₹4603 Cr | +3.2% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
LAURUSLABS vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| GLENMARK GLENMARK | — | — | Pending | 11.8% | — |
| ALKEM ALKEM | — | — | Pending | 17.4% | — |
| ABBOTINDIA ABBOTINDIA | — | — | Pending | 33.4% | — |
| AUROPHARMA Aurobindo Pharma Limited | +36.3% | 59 | Undervalued | 10.7% | — |
| MANKIND Mankind Pharma Limited | -38.3% | 40 | Overvalued | 13.7% | — |
Click a ticker to view its fair-value analysis.
Dividend History
17 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹7.60/sh
Last payout
2025-10-31
₹0.80
Peak payout
₹1.20
Trailing yield
0.14%
Amounts parsed from NSE subject lines; percent-of-face-value declarations are not converted and shown as missing.
Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of LAURUSLABS →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for LAURUSLABS →
Compare
Head-to-head with peers
Compare LAURUSLABS side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse LAURUSLABSNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.